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Abstract
Background: Sall4 is a key factor for the maintenance of pluripotency and self-renewal of embryonic stem cells
(ESCs). Our previous studies have shown that Sall4 is a robust stimulator for human hematopoietic stem and
progenitor cell (HSC/HPC) expansion. The purpose of the current study is to further evaluate how Sall4 may affect
HSC/HPC activities in a murine system.
Methods: Lentiviral vectors expressing Sall4A or Sall4B isoform were used to transduce mouse bone marrow
Lin-/Sca1+/c-Kit+ (LSK) cells and HSC/HPC self-renewal and differentiation were evaluated.
Results: Forced expression of Sall4 isoforms led to sustained ex vivo proliferation of LSK cells. In addition, Sall4
expanded HSC/HPCs exhibited increased in vivo repopulating abilities after bone marrow transplantation. These
activities were associated with dramatic upregulation of multiple HSC/HPC regulatory genes including HoxB4,
Notch1, Bmi1, Runx1, Meis1 and Nf-ya. Consistently, downregulation of endogenous Sall4 expression led to
reduced LSK cell proliferation and accelerated cell differentiation. Moreover, in myeloid progenitor cells (32D),
overexpression of Sall4 isoforms inhibited granulocytic differentiation and permitted expansion of undifferentiated
cells with defined cytokines, consistent with the known functions of Sall4 in the ES cell system.
Conclusion: Sall4 is a potent regulator for HSC/HPC self-renewal, likely by increasing self-renewal activity and
inhibiting differentiation. Our work provides further support that Sall4 manipulation may be a new model for
expanding clinically transplantable stem cells.
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Background
Hematopoietic stem cells (HSCs) are rare cells defined
by their unique ability to self-renew and their ability to
replenish all blood cell types in the body. Under normal
conditions however, only a small number of HSCs enter
cell division to generate daughter cells and supply
mature lineages. Thus a key question is how these HSCs
are regulated for their self-renewal and multipotency
properties. Scientists have tried to expand clinically
transplantable HSCs ex vivo, mainly by optimizing the
use of bioactive proteins and various hematopoietic
cytokines. The few genes that have been reported to
effectively expand HSCs ex vivo include the transcrip-
tion factor homeobox B4 (HoxB4), Notch family recep-
tors, as well as Wnt signaling proteins [1-3]. However,
the long term outcome for clinical therapy using HSCs
treated with these factors still needs to be further
elucidated.
Sall4 is a zinc-finger transcription factor and is essen-
tial for developmental events [4,5]. We and others have
previously reported that Sall4 plays important roles in
maintaining the properties of embryonic stem cells
(ESCs) by interacting with transcription factors Oct4
and Nanog [6-9]. In stem cells, Sall4 functions as both
an activator and a repressor of gene transcription
depending on the cell context. It suppresses important
differentiation genes and activates key pluripotency
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genes [9,10]. Sall4 also plays positive roles in the repro-
gramming of differentiated cells to ESC-like cells, and
generation of induced pluripotent stem cells (iPS)
[11-13]. We and others have determined that Sall4 exists
as two isoforms (Sall4A and Sall4B), and they have
unique and overlapping functions [14-16]. Interestingly,
Sall4 is one of the few genes that are also involved in
adult tissue stem cells [17,18], and its protein expression
is always correlated with the presence of stem and pro-
genitor cell populations in various organ systems includ-
ing bone marrow (BM) [16]. Importantly, SALL4 has
been identified as a robust expanding factor for human
HSCs [19]. We have recently studied the roles of Sall4
isoforms in controlling murine HSC/HPC properties.
Our data indicate that a certain level of expression of
Sall4 isoforms is necessary for normal HSC/HPC activ-
ity. Moreover, both Sall4A and Sall4B isoforms act as
potent regulators of HSC/HPC self-renewal.
Results
Sall4 isoforms enhance and support murine LSK cell
proliferation
Given the selective expression pattern of SALL4 proteins
in hematopoietic stem/progenitor cell compartments
[16], we asked whether increased expression of SALL4
isoforms may affect HSC/HPC phenotypes. To study this,
mouse HSC/HPC s (Lin-, Sca-1 +, c-Kit +; LSK cells)
were isolated and transduced with lentiviruses carrying
either GFP alone (control), or together with Sall4A or
Sall4B isoform. All GFP positive cells were determined by
either fluorescence microscope inspection or flow cyto-
metric analysis (Additional file 1: Figure. S1a, and data
not shown). We next performed western analysis to
assess the expression of Sall4 isoforms in infected
NIH3T3 fibroblast cells. It was found that these cells
expressed the appropriate Sall4A or Sall4B protein at 160
and 90 kDa. As negative control, the empty GFP vector
did not generate Sall4A or Sall4B bands (Additional
file 1: Figure. S1b).
In culture, all LSK cells with and without Sall4 trans-
duction were strictly cytokine dependent, which were not
able to survive more than 5 days in the absence of cyto-
kines (100 ng/ml mSCF, 6 ng/ml mIL-3 and 10 ng/ml
hIL-6) or in each alone (data not shown). Thus, Sall4
overexpression did not convert cells to cytokine indepen-
dence. In the combination of cytokines, the Sall4A or
Sall4B transduced cells exhibited a ~2 fold increase in
the rate of proliferation relative to the GFP control group
at day 15 and thereafter (Figure 1a). During the second
week, a small part of adherent cells were seen on the bot-
tom of GFP control culture dishes, many floating cells
resembled granulocytes and exhibited various shapes and
different sizes, while these were barely observed in Sall4A
or Sall4B infected cultures, in which cells were non-
adherent, uniquely round, spherical and at similar size
(Figure 1b). We performed flow cytometry assay at day
14 to test their surface antigens. It was found that most
Sall4 treated HSC/HPCs retained immature surface phe-
notypes (Sall4A group: Sca-1+c-Kit+, 71.2% and Lin+,
10.8%; Sall4B group: Sca-1+c-Kit+, 64.5% and Lin+,
14.3%). By contrast, many GFP treated HSC/HPC cells
exhibited differentiating markers (Sca-1+c-Kit +, 42%
and Lin+, 37.5%) (Figure 2). After three weeks, the GFP
treated LSK cells gradually stopped proliferating and
were no longer viable after day 30. However, both Sall4A
and Sall4B transduced cells continued to proliferate at a
stable doubling time of about 48 hours and proliferated
indefinitely in culture (> 4 months). These in vitro stu-
dies were repeated in two additional experiments and
similar results were obtained.
To date, only several factors have been reported to
expand HSC/HPCs in vitro while their stem cell charac-
teristics were not impaired. To test whether Sall4-
expanded HSC/HPCs may retain immature properties
after long term culture, we repeated flow cytometry
assays after 6 weeks of culture. We found that there were
more than 70% of expanded cells retaining immature sur-
face features (Sall4A group: Sca-1+, 79%, c-Kit +, 64%
and Lin+, 21%; Sall4B group: Sca-1+, 75%, ckit+, 48% and
Lin+, 22%). In addition, more than sixty percent of these
cells were still Sca-1 positive even after 3 months culture
(data not shown). These results indicate that overexpres-
sion of Sall4 isoforms is capable of enhancing and sup-
porting primitive hematopoietic cells in the presence of
combined cytokine stimulations.
Enhanced HSC/HPC activity by forced expression of Sall4
isoforms
Next, we conducted reconstitution assays to evaluate
Sall4-expanded HSC/HPC function in vivo. After 10-day
cultures, Sall4 or GFP treated cells were collected, and
2 × 106 cells (Ly5.2+) were intravenously transfused into
sublethally irradiated (500 rad) Ly5.1 mice (GFP group,
N = 4; Sall4A group, N = 4; and Sall4B group, N = 3).
Two weeks after transfusion, the percentages of trans-
planted Ly5.2+ cells in peripheral blood mononuclear
cells (PBMCs) were similar among all groups, as detected
by flow cytometry assays with multiple lineage-specific
antibodies (GFP group, 9.28%; Sall4A group, 10.0%; and
Sall4B group, 12.3%, Figure 3a). However, the Ly5.2+
blood cells in recipient mice deriving from Sall4 trans-
duced cells rose over months and surpassed the contribu-
tion from the GFP control-transduced HSC/HPCs by
week 20 and week 50 (Figure 3b). Further more, these
Ly5.2+ cells were able to reconstitute granulocyte, T
cells, and B cells, as well as immature blood cells, as indi-
cated by expression of GR-1, CD4/8, B220 and Sca-1 in
BM cells respectively (Figure 4).
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We further performed competitive repopulation assays
to determine the activity of Sall4 transduced HSC/HPCs
with day14 ex vivo cultured cells. Varying doses of cells
baring Ly5.2 antigens were mixed with a constant number
of non-transduced competitive BM cells (2 × 105, Ly5.1+),
and injected into lethally irradiated (900 rad) congenic
mice (Ly5.1). After 3 months, the contributions of control
or Sall4 transduced HSC/HPCs to the cellularities of
Figure 1 Over-expression of Sall4 isoforms enhanced and supported LSK cell growth in culture. (a) Viable cell numbers were counted for
each group of LSK cells at different days (N = 4). Error bars represent standard error of the mean. (b) Morphology observation of GFP control or
Sall4 isoforms transduced LSK cells under microscope inspection at different days. GFP transduced LSK cells grew relatively slower than Sall4
treated LSK cells and died after 4 weeks of culture, while the latter continued to proliferate in dishes.
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mature lineages were measured by Ly5.2 antigen expres-
sion of peripheral blood cells. In each group, proportion of
recipients exhibiting at least 5% donor-derived (Ly5.1+)
leukocytes was determined and scored as positive only in
which donor-derived (test) cells were detectable among
B220+, CD4/CD8+ and Gr-1+ compartments. As shown
in Figure 5a, when 2 × 104 donor cells were mixed with
2 × 105 competitive cells, Sall4A transduced LSK cells
contributed to the repopulation of 3 of 4 recipients. Simi-
larly, Sall4B transduced LSK cells contributed substantially
to the repopulation of 4 of 4 recipients (Ly5.2+ cell per-
centage > 5%), whereas repopulation mediated by GFP
control cells was not detected. When the number of
infused cells was raised to 2 × 105 cells, both Sall4A and
Sall4B transduced cells repopulated 4 of 4 recipients,
whereas GFP transduced cells did not. Taken together,
these data indicated that overexpression of Sall4 increased
the repopulation activity of HSC/HPCs.
Of note, however, though HSC/HPCs were expanded
by sustained ectopic expression of Sall4 isoforms and
exhibited enhanced repopulating activity, when trans-
planted into lethally or sublethally irradiated syngeneic
recipients, the mice grew normally and were apparently
healthy. Analysis of percent chimerism of donor cells in
each hematopoietic lineage confirmed that Sall4-trans-
duced HSC/HPCs retained full differentiation capacity
and no dramatic changes of lineage percentages were
found (Figure 5b, 4 and data not shown).
To evaluate long-term safety issues such as myelopro-
liferative neoplasm (MPN)-like features, we transduced
SALL4 isoforms to mouse LSK cells and then performed
syngeneic transplantations to allow for long-term follow-
up. As shown in Table 1, no MPN-like phenotypes were
exhibited for more than 11 months (more than 50% life-
span in mice) or even more than 17 months post syn-
geneic transplantation (n = 18). Our studies are
Figure 2 Flow cytometry assays by using individual antibodies revealed that most Sall4A or Sall4B treated LSK cells retained
immature surface phenotypes after 2 weeks culture, while GFP control LSK cells exhibited increased lineage differentiation. The
lineage cocktail consists of antibodies against CD5, CD45R, CD11b, Ter119, and GR-1. Experiments were repeated at least four times and a
representative case is shown.
Yang et al. Journal of Hematology & Oncology 2011, 4:38
http://www.jhoonline.org/content/4/1/38
Page 4 of 14
Figure 3 Enhanced HSC/HPC activity by forced expression of Sall4 isoforms. GFP control or Sall4 -transduced LSK cells (Ly5.2+, 2 × 106
cells, day-10) were transplanted into sublethally irradiated mice in combination with 1 × 105 normal BM cells with Ly5.1 phenotype. Four mice
received GFP or Sall4A treated LSK cells and three mice received Sall4B treated LSK cells. (a) The population of donor cells (Ly5.2+) in the
peripheral blood of the recipient mice was examined by flow cytometry assays with the indicated antibodies at 2 weeks after BM transfusion. (b)
The Ly5.2+ cell percentages within the peripheral white blood cells of recipients were measured at 2, 20, and 50 weeks after transplantation of
indicated lentivirus-infected BM cells. Error bars represent standard error of the mean.
Figure 4 The lineage (Gr-1, B220 and CD4/CD8) and primitive cell (Sca-1) distribution of Ly5.2+ cells was examined with the indicated
antibodies for each group. The data shown derive from three experiments with similar results.
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Figure 5 Competitive repopulation assays were performed by using different amount of cultured cells (day-14) per recipient mouse.
(a) Three months after transplantation, the percentage of regenerated lineages contributed from donor cells which bore Ly5.2 antigen is plotted.
(b) For each group, percent chimerism in each lineage is presented.
Table 1 Status of mice after being transplanted with Sall4 expanded cells
Strain Number
of mouse
Number of injected cells Month post
transfusion
Phenotype
C57B/6 4 Sall4A expanded cells, 2 × 106 17 WT-like
B6.SJL 2 Sall4A expanded cells, 4 × 106 15 WT-like
B6.SJL 4 Sall4A expanded cells, 6 × 106 11 WT-like
B6.SJL 3 Sall4B expanded cells, 4 × 106 15 WT-like
B6.SJL 5 Sall4B expanded cells, 6 × 106 11 WT-like
B6.SJL 2 GFP-infected cells, 4 × 106 15 WT-like
B6.SJL 7 GFP-infected cells, 6 × 106 11 WT-like
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consistent with the finding that ex vivo expansion of
HSC/HPCs mediated by SALL4 is still cytokine depen-
dent, which is also consistent with that seen in HoxB4
mediated HSC/HPC expansion.
Down-regulation of Sall4 accelerated differentiation of
HSC/HPCs
We previously showed that Sall4 was exclusively expressed
in CD34 positive hematopoietic stem/progenitor cells [16].
To further test the effect of Sall4 in LSK cells, we per-
formed a Sall4 knockdown study in isolated mouse BM
LSK cells by an RNA interference strategy as previously
described [20]. After 10 days culture under puromycine
selection (1.2 μg/ml), a ~62% reduction of Sall4 mRNA
levels by #7412 expressing retrovirus was confirmed by
qRT-PCR (Figure 6a). We found that Sall4-reduction LSK
cells exhibited a decreased proliferation rate relative to the
pRS control or non-treated cells (Figure 6b). In addition,
reduction of endogenous Sall4 in LSK cells caused
increased lineage differentiation markers (Sca-1+: 48 ± 7%
versus pRS control: 63.3 ± 9%; cKit+:40 ± 6% versus pRS
control: 54 ± 6%, and Lin+:42 ± 3% versus pRS control:
25 ± 3%, N = 3) during the two weeks of culture in dishes
(Figure 7). These results suggest that proper expression of
endogenous Sall4 is required for the self-renewal activity
of the HSC/HPCs.
Sall4 up-regulates multiple important HSC/HPC regulators
We have mapped SALL4 global gene targets using chro-
matin-immunoprecipitation followed by microarray hybri-
dization (ChIP-chip) in myeloid leukemic NB4 cells as
well as normal human CD34+ BM cells ([20], and unpub-
lished data). Bmi1, TPO, Runx1, c-Myc, CD34, Meis1 and
Nf-ya were identified as potential Sall4 downstream targets
in both cell types. To further test if Sall4 is able to regulate
these gene expressions, we performed qRT-PCR assays.
We detected mRNA levels of Sall4 isoforms as well as
some important HSC/HPC regulatory genes at day 7 post
lentiviral transduction. Cells were collected and total
RNAs were prepared and subjected to qRT-PCR assays.
Results showed that in Sall4A or Sall4B transduced LSK
cells, there were ~40 and ~20 fold increases of relevant
Sall4A or Sall4B mRNA levels as compared with GFP con-
trol transduced cells, (this further confirms a successful
Sall4 lentiviral transduction). Of note, transcripts of Bmi1,
HoxB4, Notch1, Runx1, CD34, Meis1 and Nf-ya were all
significantly activated, exhibiting a 2.5~15 fold up-regula-
tion when cells were treated with Sall4 isoforms (Figure 8).
ALL of these genes have been reported to play active roles
in maintaining short term or long term HSC proliferation.
In addition, Sall4 isoforms dramatically stimulate several
molecules that are implicated in the Wnt/beta-catenin sig-
naling pathway which is essential for HSC growth, includ-
ing c-Myc, cyclin D1 and cyclin D2.
Sall4 inhibits myeloid progenitor differentiation
We have performed in vitro colony forming assay to evalu-
ate effects of Sall4 isoforms on hematopoietic cell growth
and progenitor differentiation. Mouse BM cells were iso-
lated and infected with Sall4- expressing lentivirus. After
four days, 104 cells were mixed with MethoCult® medium
and seeded in dishes for colony formation. As shown in
Figure 9a and 9b, both Sall4A and Sall4B transduced cells
could generate various colonies including CFU-GM, CFU-
GEMM, and BFU-E since day 9. However, the total num-
bers of each type of colony are lower than that from the
GFP control infected cells. Two additional experiments
with various initial seeding cell numbers showed similar
results (data not shown). These experiments indicate that
over-expression of Sall4 isoforms down-modulate myeloid
differentiation versus proliferation from early primitive
cells.
We next extended our study to a myeloid progenitor cell
line (32D), to determine how Sall4 may affect hematopoie-
tic progenitor cell differentiation. 32D cells were cultured
and infected with empty GFP control or Sall4 expressing
lentiviruses. The transduction efficiency was more than
80% as judged by fluorescent observation as well as flow
cytometry assays (Additional file 2: Figure S2). During
culture, we found that the 32D cells with or without trans-
duction of Sall4 isoforms are all strictly IL-3 dependent,
which are unable to grow when removed from IL-3. Thus,
over-expression of Sall4 isoforms did not convert the 32D
cells to cytokine independence. In agreement with pre-
vious reports [21,22], 32D cells proliferate as undifferen-
tiated blasts when maintained in IL-3, but differentiate
into mature granulocytes when stimulated with G-CSF
(Figure 10a. i, ii). However, when cultured with G-CSF but
in the absence of IL-3, control 32D cells died after 5-6
days. By contrast, the Sall4 A or Sall4 B transduced 32D
cells proliferated at a 3 to 6-fold higher rate than the con-
trol counterparts in the same media and then grew indefi-
nitely (Figure 10b). In addition, these cells retained
undifferentiated blast morphology in the presence of G-
CSF but lack of IL-3 (Figure 10a, iii). This study indicates
that constitutive expression of Sall4 inhibits G-CSF
induced granulocytic differentiation and permits expan-
sion of undifferentiated cells in 32D myeloid progenitors.
Discussion
We recently reported that SALL4 is a robust expanding
factor for human HSC/HPCs [19]. In the current study,
we demonstrate that both Sall4A and Sall4B isoforms
also stimulate sustained cell proliferation of murine
HSC/HPCs (> 4 months in culture) while their capacity
of multi-lineage differentiation was not impaired. Simi-
larly, when Sall4 expanded cells were transfused into irra-
diated mouse recipients, no abnormal hematopoietic or
leukemic features were observed even after 17 months of
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BM transplantation (n = 18). This study is consistent
with the finding that HSC/HPC expansion mediated by
Sall4 is still under cytokine control. In fact, in our pre-
vious transgenic mouse studies of Sall4B overexpression
controlled by a universal CMV promoter, there was an
increased incidence of leukemic formation in older mice
[16]. Similar studies with Sall4A overexpression under
the same promoter, however, were free of leukemic for-
mation (N = 170, five transgenic mouse lines, data not
shown) after 2 years of observation. This could be due to
Figure 6 Sall4 reduction induced decreased LSK cell proliferation and accelerated differentiation. Freshly isolated BM LSK cells were
cultured and infected with pRS control retrovirus or expressing Sall4-specific short-hairpin RNA (#7412). Cells were grown with puromycin (1.2
μg/ml) selection for 10 days. (a) Total RNA was isolated from cells and subjected to qRT-PCR analysis to determine relative Sall4 mRNA
expression levels in control and #7412 treated cells. (b) Viable cell numbers were counted for each group at different days. The data shown
represent three independent replicates. Error bars represent standard error of the mean.
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Figure 7 Flow cytometry assay was performed using anti-Sca1, anti-cKit or lineage antibody cocktail for each group at day10. A
representative case is shown.
Figure 8 Sall4A or Sall4B overexpression induces the expression of important HSC regulatory genes in cultured LSK cells. Murine Lin-Sca-1+
cells were infected with lentiviruses each containing Sall4 isoform or GFP control, cultured for 7 days, and GFP+ LSK cells were isolated by FACS. Total
RNA was extracted and mRNA for the indicated genes was measured by qRT-PCR. Error bars represent standard error of the mean (N = 3).
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an abnormal niche resulting from dysregulated SALL4B
expression in various mouse tissues throughout the
mouse development with this universal CMV promoter
and/or SALL4B may bear oncogenic potential.
In isolated mouse LSK cells, forced expression of Sall4
isoforms dramatically stimulate multiple known HSC
regulators, such as Notch1, HOXB4, cMyc, CyclinD1,
CyclinD2, Bmi1, Nfya, Runx1and Meis1. This is of great
interest since all of these factors play important roles in
regulating HSC activity [23-26]. Specifically, Notch1 and
HOXB4 are thought to be highly interesting candidates
for therapeutic stem cell expansion [27]. cMyc may act
as a downstream mediator of both factors in murine
HSCs, while the trimetric transcription factor Nfya is
able to activate multiple HSC regulatory genes including
HOXB4 [28,29]. The transcription factors Meis1, Runx1
and the poly comb gene Bmi1 are all expressed at high
levels in HSCs and required for cell activity [30-32].
Figure 9 CFU assays of Sall4-transduced BM cells. BM cells were isolated and infected with GFP control or Sall4 expressing lentivirus. Four
days later, 104 cells per dish were plated and colony numbers (> 100 cells) were counted at different days (a). Various CFU types were recorded
at day 12 (b).
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Though whether/how Sall4 directly regulates other fac-
tors is unresolved, in our previous ChIP-chip study on
mouse ESCs, Sall4 bound approximately twice as many
annotated genes within promoter regions as Nanog and
approximately four times as many as Oct4 [7]. More-
over, Sall4 seems to act as a “central tower of pluripo-
tency” in ES cells in association with Oct3 ⁄ 4, Sox2 and
Nanog [33,34]. Further detailed studies are required to
elucidate whether it may also function as a master con-
troller in modulating genetic networks within the HSC
system.
Another discovery is the finding of how overexpression
of Sall4 isoforms affects G-CSF induced granulocytic dif-
ferentiation. The results obtained here were similar as
compared with the Sall4 activities in the human system
[19]. We have hypothesized that the Sall4 gene is also
involved in mediating cell fate decisions during hemato-
poiesis, helping to regulate the exquisite balance among
self-renewal, differentiation, and proliferation required
for normal blood formation. Our findings demonstrate
that sustained activation of both Sall4A and Sall4B iso-
forms inhibits granulocytic differentiation of 32D mye-
loid progenitors, supporting the view that Sall4 is capable
of influencing cell fate determination in hematopoietic
cells. This may also explain, at least in part, why Sall4 iso-
forms are expressed preferentially in HSCs, down-regu-
lated rapidly in HPCs, and absent in the differentiated
lineage populations.
Figure 10 Overexpression of Sall4 immortalized 32D cells and blocked G-CSF dependent differentiation. (a)Wright-Giemsa staining of
32D cells shows morphology of 32D cells with IL-3 alone (i), with G-CSF alone (ii), or transduced with Sall4A and with G-CSF alone (iii). (b)
Growth curves of Sall4-32D cells cultured with G-CSF alone. In cells that were transduced with Sall4A or Sall4B, a 5 or 4-fold increase in the
number of viable cells was observed from day 1 to 6.
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In summary, our work demonstrates that the potent
stem cell factor Sall4, which is preferentially expressed
within the HSC/HPC pool during hematopoiesis, acti-
vates and integrates multiple genetic pathways responsi-
ble for the precisely controlled proliferation and
differentiation of HSC/HPCs. Sall4 is thus an excellent
candidate for the genetic manipulation of HSC/HPC
self-renewal in vivo and in vitro.
Methods
Mice
C57Bl/6J (Ly5.2) and congenic C57Bl/6.SJL-Ly5.1-Pep3b
(Ly5.1) mice at 8-12 weeks of age were obtained from
The Jackson Laboratory (Bar Harbor, ME). All animal
experiments were preapproved by the Office of Labora-
tory Animal Welfare, Institutional Animal Care and Use
Committee.
Gene cloning and lentiviral transduction
The full-length cDNA of mouse Sall4A and Sall4B were
cloned into the SalI/NotI site of entry vector pENTR3C
(Invitrogen, Carlsbad, CA). A Gateway LR reaction was
carried out to subclone the cDNA into the lentiviral mam-
malian expression vector pDEST-CMVFG12 [35], which
contains reading frame of the enhanced green fluorescent
protein (EGFP). The obtained lentiviral constructs were
confirmed by PCR reaction, enzyme digestion and gene
sequencing. To generate lentivirus, the expression vectors
were transfected into 293FT packaging cells (Invitrogen)
along with pSPAX2 and pMD2.G plasmids (Addgene Inc.,
Cambridge, MA) for 48 hrs, then pooled filtered superna-
tants were used to infect cells in the presence of polybrene
(8 μg/ml, Millipore, Billerica, MA).
For lentivirus transduction, the isolated LSK or Lin-/
Sca-1+ cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum (FBS)
in the presence of mSCF (100 ng/ml), mIL-3 (6 ng/ml)
and hIL-6 (10 ng/ml). The cells (~1 × 106 per ml) were
then incubated with high titer lentivirus (~1 × 106 per ml)
for 24 hours before being replaced with fresh media. For
cultured 32D cells, lentivirus was added in conditioned
medium (RMI1640 supplemented with 10% FBS) in the
presence of mIL-3 (1 ng/ml) for 24 hours, then fresh
media was used thereafter. Cytokines were purchased
from ProSpec-Tany TechnoGene Ltd (Rehovot, Israel).
SDS-PAGE and western blotting
Total cell lysates prepared from 1 × 105 wide type or len-
tiviral infected cells were electrophoresed through 7%
SDS-polyacrylamide gels, transferred to nitrocellulose
membranes, and then immunoblotted using the anti-
Sall4 monoclonal antibody (Abcam, Cambridge, United
Kingdom). Immunostained proteins were detected using
enhanced chemilluminescence blot reagents (Thermo
Fisher Scientific, Rockford, IL). Blots were detected by a
Kodak Image Station 2000 MM (Kodak, Rochester, NY).
Isolation of mouse BM hematopoietic stem/progenitor
cells
Cells were isolated from whole BM by immunostaining
with either magnetic bead isolation or fluorescence-acti-
vated cell sorting. To obtain BM, 8- to 12-week-old mice
were euthanized by carbon dioxide inhalation and the
femurs and tibias removed. A 25-gauge needle was used to
expel the marrow by a buffer solution contained phos-
phate-buffered saline (PBS), pH 7.2, 0.5% bovine serum
albumin (BSA), and 2 mM EDTA. For depletion of mature
hematopoietic cells, the Lineage Cell Depletion Kit (Milte-
nyi Biotec, Bergisch Gladbach, Germany) was used. The
lineage (CD5, CD45R, CD11b, Ter119, and GR-1) negative
cells were collected through mini MACS separation col-
umns (Miltenyi Biotech) while in a magnetic field. For
positive purification, the collected lineage negative cell
fraction were dual stained with fluorescein isothiocyanate
(FITC) conjugated anti Sca-1 and anti-FITC MicroBeads
(Miltenyi Biotech) and separated again to yield HSC/HPCs
(Lin-/Sca-1+). At this step, we confirmed that more than
95% of the separated cells were Lin-/Sca-1+ cells by flow
cytometric analysis.
In some cases, fluorescence-activated cell sorting of
Lin-/Sca-1+/c-Kit+ (LSK) was performed on the Reflection
Cell sorter (iCyt, Champaign, IL). Antibodies were pur-
chased from BD Pharmingen (San Diego, CA). Cells sorted
were propidium iodide (PI)-negative, Lin (CD5, B220,
Ter119, Mac1, and Gr-1) negative, c-Kit, Sca-1 and GFP
positive.
Preparation of peripheral blood
Peripheral blood was obtained from each mouse by tail
vein bleeding. One hundred microliters of blood was incu-
bated for 10 minutes at room temperature with 3 mL ice-
cold erythrocyte lysing solution (150 mM NH4Cl, 10 mM
NaHCO3, 1 mM EDTA, pH 7.4), washed with PBS and
resuspended in PBS and 1% paraformaldehyde (Sigma, St
Louis, MO) and kept at 4°C until analysis.
Immunostaining and flow cytometry
Freshly isolated cells or cultured cells were stained by
described fluorescence-labeled antibodies. The flow cyto-
metry data were collected by using a FACScan or FACS-
Calibur machine (Becton Dickinson, Franklin Lakes, NJ)
and analyzed by using FLOWJO or CELLQUEST software.
RNA interference (RNAi) and quantitative reverse
transcription (qRT-PCR) Analyses
RNAi mediated Sall4 knockdown and qRT-PCR analyses
were performed as reported previously [20]. The primer
sets are described in Additional file 3: Table S1.
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32D cell culture and induction of differentiation
The 32D cells were cultured as previously described
[36]. For granulocytic differentiation, IL-3 was removed
by washing cells 3 times, then G-CSF (R&D Systems,
Minneapolis, MN) was added to cells at a final concen-
tration of 200 ng/ml.
CFU assay of BM cells
Tubes of MethoCult® GF M3434 (Stem Cell Technologies,
Vancouver, BC, Canada) medium were thawed overnight
in a 4°C refrigerator. Sall4 or GFP-transduced BM cells
were prepared at 10 × the final concentration required.
Cell suspensions of 1 × 105 cells per mL were prepared
and 0.3 mL of cells were added to 3 mL of MethoCult®
medium for duplicate cultures. 1.1 mL of cells was dis-
pensed per 35 mm dish. The cells were incubated for 8-12
days at 37°C with 5% CO2 and ≥95% humidity. The BFU-
E, CFU-GM and CFU-GEMM colonies were observed
with bright field and fluorescent microscopy. CFUs were
counted under the microscope 9 days after the cells were
plated in MethoCult® medium. A colony with more than
100 cells was counted as a positive colony.
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Additional material
Additional file 1: Figure. S1. Transduction of GFP or Sall4 isoform-
expressing lentiviruses in mouse BM LSK cells or NIH3T3
fibroblasts. (a) Mouse BM Lin-Sca-1+c-Kit (LSK) cells were isolated and
infected with lentivirus as described in Methods. Images were taken 72
hours post infection, bright field (up) and fluorescent (bottom) images
illustrating the infection efficiency of lentiviral constructs containing GFP
+ Sall4A, GFP + Sall4B or GFP only. (b) A western blot analysis was
performed to confirm the expression of Sall4 isoforms in lentivirus
transduced NIH3T3 cell lines using anti-Sall4 antibodies.
Additional file 2: Figure S2. Transduction of GFP control or Sall4
isoform- expressing lentiviruses in 32D cells. (a) Bright field (up) and
fluorescent (bottom) images illustrating the infection efficiency of
lentiviral constructs containing GFP + Sall4A, GFP + Sall4B or GFP only.
Images were taken 72 hours post infection with lentiviruses. (b) Flow
cytometric assessment of virus infected cells by using anti-FITC antibody
5 days post infection.
Additional file 3: Table S1. Primer information used for qRT-PCR.
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